Circulating MicroRNA-26a in Plasma and Its Potential Diagnostic Value in Gastric Cancer

Background In the past decades, a good deal of studies has provided the possibility of the circulating microRNAs (miRNAs) as noninvasive biomarkers for cancer diagnosis. The aim of our study was to detect the levels of circulating miRNAs in tissues and plasmas of gastric cancer (GC) patients and evaluate their diagnostic value. Methods Tissue samples were collected from 85 GC patients. Plasma samples were collected from 285 GC patients and 285 matched controls. Differentially expressed miRNAs were filtered with by Agilent Human miRNA Microarray and TaqMan low density array (TLDA) with pooled samples, followed by the quantitative reverse transcription polymerase chain reaction (qRT-PCR) validation. Receiver operating characteristic (ROC) curves were structured to evaluate the diagnostic accuracy of the miRNAs. The plasma level of miR-26a in GC patients of different clinical stages was compared. Results Four miRNAs (miR-26a, miR-142-3p, miR-148a, and miR-195) revealed coincidentally decreased levels in tissue and plasma of the GC patients compared with controls, and ROC curves were constructed to demonstrate that miR-26a had a highest area under the ROC curve (AUC) of 0.882. Furthermore, miR-26a was stably detected in the plasma of GC patients with different clinical characteristics. Conclusion Plasma miR-26a may provide a novel and stable marker of gastric cancer.

[1]  Tyson V. Sharp,et al.  Suppression of AGO2 by miR-132 as a determinant of miRNA-mediated silencing in human primary endothelial cells , 2015, The international journal of biochemistry & cell biology.

[2]  Chaoqian Xu,et al.  MicroRNA-26a prevents endothelial cell apoptosis by directly targeting TRPC6 in the setting of atherosclerosis , 2015, Scientific Reports.

[3]  L. Du,et al.  Serum microRNA expression signatures identified from genome‐wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer , 2015, International journal of cancer.

[4]  Y. Doki,et al.  Circulating miR-199a-3p as a novel serum biomarker for colorectal cancer. , 2014, Oncology reports.

[5]  Jianwei Zhou,et al.  A common genetic variation in the promoter of miR-107 is associated with gastric adenocarcinoma susceptibility and survival. , 2014, Mutation research.

[6]  Hongbing Shen,et al.  A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer , 2014, British Journal of Cancer.

[7]  Haorong Wu,et al.  MiR-378 inhibits progression of human gastric cancer MGC-803 cells by targeting MAPK1 in vitro. , 2013, Oncology research.

[8]  Min Deng,et al.  miR-26a Suppresses Tumor Growth and Metastasis by Targeting FGF9 in Gastric Cancer , 2013, PloS one.

[9]  Cristina Rodríguez-Padilla,et al.  Serum Circulating microRNA Profiling for Identification of Potential Breast Cancer Biomarkers , 2013, Disease markers.

[10]  Yingjian Chen,et al.  Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer , 2012, Journal of Cancer Research and Clinical Oncology.

[11]  D. Ichikawa,et al.  Circulating microRNA in digestive tract cancers. , 2012, Gastroenterology.

[12]  Xi Chen,et al.  Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls. , 2012, Carcinogenesis.

[13]  Wei Zhang,et al.  Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. , 2012, Cancer letters.

[14]  A. Poprach,et al.  Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma , 2012, Journal of Translational Medicine.

[15]  Xi Chen,et al.  Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. , 2012, Clinical chemistry.

[16]  N. Palanisamy,et al.  Genomic Loss of miR-486 Regulates Tumor Progression and the OLFM4 Antiapoptotic Factor in Gastric Cancer , 2011, Clinical Cancer Research.

[17]  E. Kroh,et al.  Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma , 2011, Proceedings of the National Academy of Sciences.

[18]  Xi Chen,et al.  A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. , 2011, European journal of cancer.

[19]  K. Yanagihara,et al.  The metastasis-associated microRNA miR-516a-3p is a novel therapeutic target for inhibiting peritoneal dissemination of human scirrhous gastric cancer. , 2011, Cancer research.

[20]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[21]  Michael J Kerin,et al.  Circulating microRNAs as Novel Minimally Invasive Biomarkers for Breast Cancer , 2010, Annals of surgery.

[22]  C. Croce.  Causes and consequences of microRNA dysregulation in cancer , 2009, Nature Reviews Genetics.

[23]  Jackeline Agorreta,et al.  microRNA-451 Regulates Macrophage Migration Inhibitory Factor Production and Proliferation of Gastrointestinal Cancer Cells , 2009, Clinical Cancer Research.

[24]  L. Hood,et al.  Circulating microRNAs, potential biomarkers for drug-induced liver injury , 2009, Proceedings of the National Academy of Sciences.

[25]  E. Sontheimer,et al.  Origins and Mechanisms of miRNAs and siRNAs , 2009, Cell.

[26]  E. Ng,et al.  Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening , 2009, Gut.

[27]  Rong Huan,et al.  Detection of miR-106a in gastric carcinoma and its clinical significance. , 2009, Clinica chimica acta; international journal of clinical chemistry.

[28]  Joel Greshock,et al.  MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. , 2008, Cancer research.

[29]  C. Langmead,et al.  ANGIOPOIETIN-2, A REGULATOR OF VASCULAR PERMEABILITY IN INFLAMMATION IS ELEVATED IN SEVERE ACUTE PANCREATITIS AND IS ASSOCIATED WITH SYSTEMIC ORGAN FAILURE , 2008 .

[30]  X. Chen,et al.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.

[31]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[32]  A. Harris,et al.  Detection of elevated levels of tumour‐associated microRNAs in serum of patients with diffuse large B‐cell lymphoma , 2008, British journal of haematology.

[33]  J. Lötvall,et al.  Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells , 2007, Nature Cell Biology.

[34]  R. Shiekhattar,et al.  MicroRNA biogenesis and cancer. , 2005, Cancer research.

[35]  J. Schneider,et al.  Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer. , 2003, Anticancer research.

[36]  C. Haglund,et al.  CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. , 2002, Anticancer research.

[37]  T. Hirayama,et al.  Epidemiology of Stomach Cancer , 1965 .

[38]  L. Migliore,et al.  Mutation Research / Fundamental and Molecular Mechanisms of Mutagenesis , 2014 .

[39]  Michael R Hamblin,et al.  CA : A Cancer Journal for Clinicians , 2011 .

[40]  Kang Li,et al.  Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. , 2010, Biochemical and biophysical research communications.

[41]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[42]  H. Espejo,et al.  [Gastric cancer]. , 1996, Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru.